Search tips
ESCMID Global 2024
Courses & Events
Guidelines
From the archive: ECCMID and more before 2010
Search Results
Sort by:
Filter 0
Sort by
Filter
Sort by
Relevance
Date descending
Date ascending
28 April 2024 - P2522
Outcomes at test of cure by baseline pathogen and cefepime-taniborbactam or meropenem MIC in the Phase 3 CERTAIN-1 study of patients with complicated urinary tract infection (cUTI)
Greg Moeck, Leanne Gasink, Mary Beth Dorr, Hongzi Chen, Paul Mcgovern
04 October 2022 - EA01
Time to change the complicated urinary tract infection primary endpoint? The problem and a potential solution
Paul McGovern, Greg Moeck, Aaron Dane
04 October 2022 - EA03
Cefepime-taniborbactam and comparator activity in vitro against carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant P. aeruginosa (CRPA) and multidrug-resistant (MDR) Enterobacterales and P. aeruginosa from 2018-2020 global surveillance
Greg Moeck, M. Wise, M. Hackel, D. Sahm
09 July 2021 - 3285
Assessment of activity of a novel orally bioavailable β-lactam/β-lactamase inhibitor combination, ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) against Enterobacterales carrying blaOXA-48
Elise T. Zeiser, E.T. Zeiser (1), D.A. Six (2), G. Moeck (2), K.M. Papp-Wallace (1, 3)
09 July 2021 - 2128
Cefepime/taniborbactam (formerly cefepime/VNRX-5133) demonstrates potent activity versus Enterobacterales with blaOXA-48
Elise T. Zeiser, E.T. Zeiser (1), D.A. Six (2), G. Moeck (2), K.M. Papp-Wallace (1, 3)
09 July 2021 - 2144
Examining the antimicrobial activity of cefepime/taniborbactam (formerly cefepime/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States
Elise T. Zeiser, E.T. Zeiser (1), S.A. Becka (1), J.J. Lipuma (2), D.A. Six (3), G. Moeck (3), K.M. Papp-Wallace (1, 4)
14 April 2019 - P1183
Oral ceftibuten/VNRX-7145 shows equivalent activity in vitro to IV therapeutics against MDR Enterobacteriaceae
Jodie Hamrick, Cassandra Chatwin, Kaitlyn John, Christopher Burns, Luigi Xerri, Greg Moeck, Daniel Pevear
14 April 2019 - P1181
Selection of ceftibuten as the partner antibiotic for the oral beta-lactamase inhibitor VNRX-7145
Jodie Hamrick, Cassandra Chatwin, Kaitlyn John, Christopher Burns, Luigi Xerri, Greg Moeck, Daniel C. Pevear
26 April 2015 - P0713
Oritavancin disk diffusion assay can distinguish vancomycin-intermediate Staphylococcus aureus from vancomycin-susceptible S. aureus
Adam Belley, Belley, Adam *; Arhin, Francis; Moeck, Greg;
26 April 2015 - P0709
Oritavancin and comparator activities against S. aureus and Streptococcus spp. isolated from skin and skin structure infections in Europe and North America 2011-2014
Daniel Sahm, Biedenbach, D.; Lynch, T.; Arhin, F. F. ; Moeck, G.; Sahm, D. *;
12 May 2014 - O152
A single dose of oritavancin (ORI) compared to 7-10 days of vancomycin (VAN): clinical response across different lesion types in the SOLO non-inferiority studies
Greg Moeck, Corey, G.R.(1); Jiang, H.(2); Good, S.(2); Moeck, G.(2); Wikler, M.(2)*
10 May 2014 - eP418
Concordance between early (48-72 hours) and late (7-14 days post therapy) clinical response: an analysis from the solo non-inferiority clinical studies
Greg Moeck, Corey, G.R.(1)*; Good, S.(2); Jiang, H.(2); Moeck, G.(2); Wikler, M.(2);
10 May 2014 - eP174
Oritavancin does not antagonise the activity of common antibacterial agents for Gram-positive and Gram-negative infections
Adam Belley, Belley, A.(1)*; Arhin, F.F.(1); Moeck, G.(1);
10 May 2014 - eP173
Longitudinal study of the activity of oritavancin (ORI) against Staphylococcus aureus (SA) from Europe (EU) between 2011 and 2013
Francis Arhin, Sahm, D.F.(1)*; Draghi, D.C.(1); Moeck, G.(2); Arhin, F.F.(2);
10 May 2014 - eP416
Clinical outcomes by pathogen in phase 3 studies of single dose oritavancin versus 7 to 10 days of vancomycin to treat CSSTI
Francis Arhin, Moeck, G.(1)*; Arhin, F.F.(1); Jiang, H.(2); Fiset, C.(2); Draghi, D.C.(3); Sahm, D.F.(3);
10 May 2014 - eP417
The PVL gene does not impact clinical response to treatment with single dose oritavancin or 7 to 10 days of vancomycin in patients with CSSTI
Francis Arhin, Arhin, F.F.(1)*; Moeck, G.(1); Jiang, H.(2); Fiset, C.(2); Draghi, D.C(3); Sahm, D.F.(3);
28 April 2013 - P1594
In vitro activities of oritavancin and comparators against methicillin-resistant Staphylococcus aureus (MRSA) strains harbouring the novel mecC gene
Francis Arhin, F.F. Arhin*, I. Sarmiento, G. Moeck (Ville Saint Laurent, CA)
28 April 2013 - P1644
Activity of oritavancin against European bacterial pathogens associated with skin/wound and soft tissue infections and bacteraemia
Jennifer Deane, J. Deane*, C. Opeila, G. Moeck, F.F. Arhin, D. Sahm (Chantilly, US; Saint Laurent, CA)
28 April 2013 - P1645
Activity of oritavancin against European Gram-positive bacterial pathogens with problematic resistant phenotypes
Jennifer Deane, J. Deane*, C. Opiela, G. Moeck, F.F. Arhin, D. Sahm (Chantilly, US; Saint Laurent, CA)
28 April 2013 - P1605
Development of disc diffusion method for oritavancin: comparison of disc diffusion with broth microdilution reference method for Staphylococcus aureus
Laura Koeth, L. Koeth*, J. DiFranco-Fisher, F.F. Arhin, M. Marquis, G. Moeck, A. Belley (Westlake, US; St.-Laurent, CA)
Loading ...
+ load more
FAQ
To access content in the Library you need to log in with your ESCMID member or user credentials. If you haven’t registered as an ESCMID member yet, then click here to do so – or use this link to register as a user.
The most recent event-related content is usually restricted to ESCMID members, while registered users get access one year after the event. However, there are events such as ESCMID Global where attendees get priority access, no matter if they are members or registered users. In these cases, we may offer non-attendees access after paying a fee.
You may search by event name, session title or number, topic title or number or author – or by any keyword. To get the most relevant results, enter the title or name in quotation marks, e.g. "Pre-ECCMID Day on Diagnostics" or "John Doe". If no quotation marks are used, then the exact result is shown first, followed by less exact results.
You may further narrow the number of search results for most terms by applying one or several filters, using the filter window on the start page. The Category and Media Type filters work for any content. In contrast, the Date from / to filter may not apply for Publications and Guidelines. In addition, the information text below a webcast or document offers the option of filtering search results by session title, author, event or category.
We defined four "hot topic" terms that you may search for by clicking the four tiles on the start page.
Linking two or more search terms by AND will show all results containing these search terms. For example, if you are looking for results that contain both the terms viral and hospital, then enter viral AND hospital.
Link two or more search terms by OR to get all results that contain at least one of these terms. For example, if you want to get results that contain either viral or infections or COVID, then enter viral OR infections OR COVID.
Place + in front of the term that you want to be included in your search result and place - in front of the term that you do not want to be included – without blanks in between in either case. For example, if you are aiming for search results that contain viral and infection but do not contain COVID, then enter +viral +infections -COVID.
A search term preceded by an exclamation point (no blanks in between) will lead to all content that does not contain the term, e.g. !COVID.
Deselect the ticked boxes in the filter dropdowns, click "Clear" on the calendars in the Date from / to filter – or refresh the website to remove all filters at once. Additionally, you may clear all applied filters by using the relevant buttons right above the search results.
No, as copyright protection limits the viewing of video presentations to web browsers, they cannot be downloaded.
No, due to our privacy policy we cannot disclose any contact details of persons involved.